China Ovarian Cancer BRCA Testing Study

Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region

NCT03082976 ·Status: COMPLETED

Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.

NCT02341118 ·Status: TERMINATED

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

NCT06120972 ·Status: WITHDRAWN ·Phase: PHASE2

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

NCT05044091 ·Status: UNKNOWN

Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India

NCT03471572 ·Status: COMPLETED

Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma

NCT03302884 ·Status: UNKNOWN ·Phase: NA

BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary

NCT06304922 ·Status: NOT_YET_RECRUITING

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

NCT04582552 ·Status: UNKNOWN

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

NCT04337632 ·Status: UNKNOWN ·Phase: PHASE3

Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer

NCT02406235 ·Status: COMPLETED

Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands

NCT07039552 ·Status: RECRUITING

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

NCT03519230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Genetic Mutation in Epithelial Ovarian Cancer

NCT04191252 ·Status: UNKNOWN

Clinical Study of Individualized Treatment of Relapsed or Drug-resistant Advanced Gynecological Tumors Guided by PTC Model

NCT06232213 ·Status: RECRUITING

Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer

NCT02524808 ·Status: UNKNOWN

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03635489 ·Status: COMPLETED ·Phase: PHASE3

Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom

NCT00757263 ·Status: UNKNOWN

BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer

NCT02963688 ·Status: COMPLETED

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

NCT03944902 ·Status: TERMINATED ·Phase: PHASE1

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03585764 ·Status: TERMINATED ·Phase: PHASE1

HRD and Resistance to PAPPi in EOC Patients

NCT05310370 ·Status: UNKNOWN

Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2

NCT03296826 ·Status: RECRUITING

Phase II CT-2103/Carboplatin in Ovarian Cancer

NCT00069901 ·Status: COMPLETED ·Phase: PHASE2

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

NCT06173037 ·Status: COMPLETED ·Phase: PHASE2

Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer

NCT04556539 ·Status: UNKNOWN ·Phase: PHASE2